Etentamig

Summary

Etentamig (CHEMBL5314973) is a phase-3 clinical-stage antibody; indicated across 3 conditions including plasma cell myeloma and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 3 conditions
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314973
Name	Etentamig
Type	Antibody
Max phase	3

Also known as: Abbv-383, ABBV-383, Anti-bcma x acd3 t-bsab tnb-383b, Etentamig, Tnb-383b, ETENTAMIG

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
plasma cell myeloma	3	MONDO:0009693	EFO:0001378
neoplasm	2	MONDO:0005070	EFO:0000616
hereditary amyloidosis	1	MONDO:0018634	MONDO:0019438

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE1/PHASE2	5
PHASE1	5
PHASE3	1
PHASE2/PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06158841	PHASE3	RECRUITING	Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT07095452	PHASE2/PHASE3	RECRUITING	A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT03933735	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
NCT06158854	PHASE1/PHASE2	RECRUITING	A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
NCT06892522	PHASE1/PHASE2	RECRUITING	A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
NCT07420959	PHASE1/PHASE2	NOT_YET_RECRUITING	ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia
NCT07600151	PHASE1/PHASE2	NOT_YET_RECRUITING	Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
NCT05259839	PHASE1	ACTIVE_NOT_RECRUITING	A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05286229	PHASE1	ACTIVE_NOT_RECRUITING	A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
NCT05650632	PHASE1	RECRUITING	A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06223516	PHASE1	ACTIVE_NOT_RECRUITING	Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06896916	PHASE1	RECRUITING	Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT04453397	Not specified	NO_LONGER_AVAILABLE	Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).